Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 32, Issue 9, 2002, Pages 352-357

  Yang, Tsai Shen ^a   Wang, Jeng Yi ^a   Tang, Reiping ^a   Hsu, Kuan Cheng ^a   Chen, Jen Shi ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Leucovorin; Metastatic colorectal cancer; Salvage chemotherapy; UFT

Indexed keywords

AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PYRIDOXINE; STEROID; UFT; ANTINEOPLASTIC AGENT; TEGAFUR; UFT(R) DRUG; URACIL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC HEPATITIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TOLERABILITY; EXFOLIATIVE DERMATITIS; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; SALVAGE THERAPY; SEPSIS; SKIN DEFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECTAL NEOPLASMS; SALVAGE THERAPY; TEGAFUR; URACIL;

EID: 0036730401     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyf072     Document Type: Article

References (30)

1. Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 1987;3:190-214.
2. Seifert P, Baker LH, Reed MD, Vaitkevicius VK. Comparison of continuous infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal carcinoma. Cancer 1975;30:123-8.
3. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a bolus schedule in metastatic colorectal carcinomas. A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-33.
4. Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983;99:823-33.
5. Yang TS, Hsu KC, Chiang JM, Tang R, Chen JS, Changchien CR, et al. A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24 h infusion in patients with advanced colorectal carcinoma. Cancer 1999;85:1925-30.
6. Meta-analysis Group in Cancer. Efficacy of continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;17:301-8.
7. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-72.
8. El Sayed YM, Sadee W. Metabolic activation of R,S,-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. Cancer Res 1983;43:4039-44.
9. Ikenaka T, Shiraska T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979;70:353-9.
10. Tsujimoto T, Sakai S, Murata M. Concentrations of 5-FU in the tissue and serum of patients with head and neck malignant tumor by preoperative administration of UFT. Jpn J Cancer Chemother 1983;10:78-83.
11. Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998;4:2085-8.
12. Pazdur R, Lassere Y, Diaz-Canton E, Ho DH. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28 day schedule. Cancer Invest 1998;16:145-51.
13. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, et al. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-300.
14. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer 1995;75:782-5.
15. Ota K, Taguchi T, Kimura YM. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333-8.
16. Malik STA, Talbot D, Clarke PI, Osborne R, Reznek R, Wrigley PF, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990;62:1023-5.
17. Sanchiz F, Milla A. Tegafur-uracil (UFT) plus leucovorin in advanced rectal cancer. Jpn J Clin Oncol 1994;24:322-6.
18. Straw JA, Szapary D, Wynn WT. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 1984;44:3114-9.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Higgie GD, Sommadossi JP, Gross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987;47:2203-6.
21. McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 1998;77:461-5.
22. Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;1009.
23. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, et al. Biochemia modulation of fluorouracil and leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
24. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
25. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
26. Arbuck SBG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989;63:1036-44.
27. Brenckman WD, Laufman LR, Morgan ED, Stydnicki KK, Collier MA, Knick VD. Pilot trial of 5-FU with high doses oral leucovorin tablets in advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1988;376.
28. Hines JD, Aldelstein DJ, Spies JL, Giroski P, Carter SG. Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma: Plasma and tissue pharmacokinetics. Cancer 1989;63:1022-5.
29. Schilsky RL, Choi KE, Vokes EE, Guaspari A, Guarnieri C, Whaling S, et al. Clinical pharmacology of stereoisomers of leucovorin during repeated oral dosing. Cancer 1989;63:1018-21.
30. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, et al. A phase II study of weekly 24 h infusion with high-dose fluorouracil with leucovorin in colorectal cancer. J Clin Oncol 1991;9:625-30.